The South African alternative investment firm has bought one bitcoin.
3 Reasons to Sell LOCO and 1 Stock to Buy Instead
Over the past six months, El Pollo Loco’s stock price fell to $12.36. Shareholders have lost 8.8% of their capital, which is disappointing considering the S&P 500 has climbed by 8.9%. This may have investors wondering how to approach the situation.
3 Reasons to Sell MTD and 1 Stock to Buy Instead
Over the past six months, Mettler-Toledo’s shares (currently trading at $1,304) have posted a disappointing 8.9% loss, well below the S&P 500’s 8.9% gain. This may have investors wondering how to approach the situation.
Crypto Market Faces Weak Demand, Needs Trump Initiatives to Kick In, JPMorgan Says
Institutional crypto futures positioning suggests a weakness in demand, the report said.
Q3 Earnings Roundup: Sleep Number (NASDAQ:SNBR) And The Rest Of The Home Furniture Retailer Segment
Let’s dig into the relative performance of Sleep Number (NASDAQ:SNBR) and its peers as we unravel the now-completed Q3 home furniture retailer earnings season.
3 Reasons to Avoid NX and 1 Stock to Buy Instead
Quanex has gotten torched over the last six months - since August 2024, its stock price has dropped 25.5% to $20.73 per share. This may have investors wondering how to approach the situation.
Winners And Losers Of Q4: Old Dominion Freight Line (NASDAQ:ODFL) Vs The Rest Of The Ground Transportation Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Old Dominion Freight Line (NASDAQ:ODFL) and the rest of the ground transportation stocks fared in Q4.
Air Freight and Logistics Stocks Q4 Highlights: Hub Group (NASDAQ:HUBG)
Looking back on air freight and logistics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Hub Group (NASDAQ:HUBG) and its peers.
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with Viatris (NASDAQ:VTRS).
3 Reasons to Avoid OTIS and 1 Stock to Buy Instead
Otis has been treading water for the past six months, recording a small return of 4.2% while holding steady at $97.90.